pIFN (peginterferon alfa-2a)

PreclinicalSmall molecule

pIFN (peginterferon alfa-2a) is one of 2 small molecule programs targeting Refractory Melanoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory MelanomaRecruiting

Refractory MelanomaPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Refractory Melanoma

#DrugCompanyPhaseTrials

DOC1021

DDiakonos Oncology Corporation

Preclinical

1 2

pIFN (peginterferon alfa-2a)

DDiakonos Oncology Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2033

PreclinicalRecruiting

Refractory Melanoma

NCT07288112

Clinical

Trials by Indication[1]

Refractory Melanoma1 trial

Clinical Study of DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Recruiting·DDiakonos Oncology Corporation·Preclinical·NCT07288112·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pIFN (peginterferon alfa-2a). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pIFN (peginterferon alfa-2a) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pIFN (peginterferon alfa-2a). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Diakonos Oncology Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDiakonos Oncology Corporation

pIFN (peginterferon alfa-2a)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2033

Trials by Indication[1]

Refractory Melanoma1 trial

References

Drug Info

Quick Facts

Related News